DUBLIN--(BUSINESS WIRE)--The "Global Epinephrine Autoinjector Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
The epinephrine autoinjector market is poised to grow by $ 762.51 mn during 2020-2024 progressing at a CAGR of 7% during the forecast period. The report on the epinephrine autoinjector market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of allergies, technological advances and marketing strategies. In addition, increasing prevalence of allergies is anticipated to boost the growth of the market as well.
The epinephrine autoinjector market analysis include end-user segment and geographic landscapes.
This study identifies the tentative product launches as one of the prime reasons driving the epinephrine autoinjector market growth during the next few years. Also, growing awareness about epinephrine autoinjectors and patient assistance programs will lead to sizable demand in the market.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epinephrine autoinjector market vendors that include Adamis Pharmaceuticals Corp., ALK-Abello AS, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Kaleo Inc., Lincoln Medical Ltd., Mylan NV, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.. Also, the epinephrine autoinjector market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Key Topics Covered:
1. Executive Summary
- Market Overview
2. Market Landscape
- Market ecosystem
- Value chain analysis
3. Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
4. Five Forces Analysis
- Five Force Summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
5. Market Segmentation by Dosage
- Market segments
- Comparison by Dosage
- 0. 30gm - Market size and forecast 2019-2024
- 0. 15gm - Market size and forecast 2019-2024
- 0. 50gm - Market size and forecast 2019-2024
- Market opportunity by Dosage
6. Market Segmentation by Age Group
- Market segmentation by Age Group
7. Market Segmentation by End-user
- Hospitals and clinics
8. Customer landscape
9. Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Volume driver - demand-led growth
- Market challenges
- Market trends
10. Vendor Landscape
- Vendor landscape
- Landscape disruption
- Competitive Scenario
11. Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Adamis Pharmaceuticals Corp.
- ALK-Abello AS
- Amneal Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Kaleo Inc.
- Lincoln Medical Ltd.
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
For more information about this report visit https://www.researchandmarkets.com/r/hkz05m